Kornimate/medical-research-clean huggingface dataset:
clinical significance of 64-slice multidetector coronary ct angiography to evaluate the prevalence and severity of coronary artery disease in renal transplant recipients

Conditions: Kidney Transplant Recipient

Summary: the aim of this study is to evaluate the clinical usefulness of 64-slice multidetector coronary ct angiography (mdcta) in renal transplant recipients who had no previous coronary artery disease (cad). primary endpoint is to assess the prevalence and severity of coronary artery disease in patients post-transplant 6 to 12 months. cad can be diagnosed noninvasively with similar accuracy of coronary angiography using mdcta. early detection and intervention of cad may provide survival benefit in renal transplant recipients.


Eligibility criteria:
inclusion criteria: 1. age ≥ 40 yrs 2. renal transplant recipient at post-transplant 6 to 12 months 3. stable graft renal function: ckd-epi (chronic kidney disease epidemiology collaboration) equation ≥45 ml/min/1.75m2 4. patients who had no previous cad exclusion criteria: 1. unstable graft renal function 2. history of acute kidney injury within 3 months 3. allergic history to contrast agent 4. irregular heart beat 5. multiorgan transplant recipients 6. pregnancy 7. patients who do not consent to this study

Keywords: multidetector coronary ct angiography, renal transplantation
peripheral blood and/or bone marrow, including detection of occult metastases, in patients with melanoma

Conditions: Melanoma

Summary: the purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.

patients with melanoma can succumb to subclinical metastatic disease, not detectable at presentation by conventional physical examination, hematologic and biochemical screening, or radiologic evaluation. more intensive radiologic evaluation with ct or radioisotope scanning has not proven to be useful. what may be useful is a more sensitive method of staging melanoma patients at presentation, specifically evaluating them for subclinical systemic disease.

Eligibility criteria:
inclusion criteria: msk patients with histologically confirmed melanoma of any site and at least one of the following: * primary tumor \> 4.0 mm thick (ajcc stage iib) * clinically or histologically positive regional nodes (ajcc stage iii) * any in transit disease (ajcc stage iii) * any systemic metastases (ajcc stage iv)

Keywords: histologically confirmed melanoma of any site
effects of the proprioceptive neuromuscular facilitation for promoting muscular irradiation

Conditions: Motor Disorders

Summary: this study aims to evaluate the effects of proprioceptive neuromuscular facilitation (pnf) patterns delivered to the upper limb, lower limb and trunk for promoting motor irradiation to the contralateral lower limb.


Eligibility criteria:
inclusion criteria: * right-handed * sedentary * healthy * body mass index between 18.5 - 24.9 kg/m2 exclusion criteria: * having any injuries that prevented the implementation of the proposed activities * being pregnant
excessive supraventricular activity and atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter; Supraventricular Beat, Premature; Premature Supraventricular Beats; Premature Atrial Complex; Extrasystole, Atrial

Summary: the aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (esvea) on holter recording should be subjected to prolonged screening with event loop recorder in order to detect previously undiagnosed atrial fibrillation / flutter. other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in esvea and control group as well as progression of atrial cardiomyopathy in esvea patients.

excessive supraventricular ectopic activities (esvea) are a common finding on long-term ecg recordings and have a connection to atrial cardiomyopathy, incident af, stroke and mortality. holter recording from 2022 preformed at danderyd hospital will be screened in order to identify 125 recordings with esvea, defined as at least 30 atrial ectopic beats/hour or a supraventricular run of at least 20 consecutive beats. participants fulfilling eligibility criteria will be offered prolonged af screening with continuous holter recording during 14 days. a matched control group (125 participants) without esvea will also be screened using same method. cardiovascular data from medical records will be collected in order to obtain information regarding co-morbidities and being able to assess cha2ds2-vasc score. participants will be asked to fill in a questionnaire. samples of blood will be collected at index time, after 21± 3 months for further analysis with the aim of identifying biomarkers for atrial fibrillation. during these two time periods echocardiography, 24 hour ambulatory blood pressure monitoring and assessment af artery stiffness with arteriograph will also be preformed. the study population will after 21± 3 months be subjected to renewed screening with holter in order to examine the persistence of excessive supraventricular activity. four years after the completion of screening visits, data from patient records and information thorough telephone interview and/or data from swedish patient register, swedish dispensed drug register will be collected

Eligibility criteria:
inclusion criteria: patients with at least 30 supraventricular extra systole (sves)/h or a supraventricular run of at least 20 beats on a holter recording. exclusion criteria: age \ 89 years atrial fibrillation / flutter lifelong treatment with oral anticoagulant patients with implantable cardiac device congestive heart failure (chf) with ejection fraction (ef) ≤ 30% severe valvular heart disease

Keywords: excessive supraventricular ectopic activity
surrogate markers of portal pressure

Conditions: Portal Hypertension; Cirrhosis

Summary: this is a prospective longitudinal study that will evaluate if changes (pre and post therapy) in indocyanine green (icg) retention test and liver stiff ness (ls) and spleen stiffness (ss) as measured by acoustic radiofrequency impulse (arfi) correlate with changes in portal pressure as determined by the hepatic vein pressure gradient (hvpg) in patients with compensated hepatitis c virus (hcv) cirrhosis undergoing antiviral therapy.

subjects will be recruited from the outpatient setting of the west haven va medical center and the yale liver clinic. subjects between 18-85 years of age with compensated cirrhosis due to chronic hepatitis c virus (hcv) infection who will be starting anti-viral therapy to treat hcv within the next 3 months will be eligible for this study. 33 subjects (assuming 10% loss to follow-up) will be recruited and their participation will last from 6-12 months. the expected duration of the study is 2 years. the primary end point of the study is to correlate the change (from baseline to after completing anti-hcv therapy) in icg retention test, ls and ss as measured by arfi with hvpg. after consent has been obtained, subjects will undergo icg retention test, arfi imaging and hvpg measurements before and after hcv therapy. blood samples, demographic and clinical data will be collected before and after hcv therapy. correlations between changes in hvpg and changes in icg, ls and ss will be assessed. with 30 patients , we will have 80% power to perform a hypothesis test of the pearson correlation assuming an observed correlation of 0.70 and a two-sided type i error rate of 0.05.

Eligibility criteria:
inclusion criteria: * age 18-85 * hcv infection (hcv-rna positive) * compensated cirrhosis will be defined histologically and/or clinically (presence of compatible lab findings (platelet count ≤ 150,000, total bilirubin ≥ 2, serum albumin ≤ 3.5, inr ≥ 1.2) plus compatible physical exam features (cutaneous stigmata, gynecomastia in men, or splenomegaly) or compatible radiological findings (nodular liver surface, splenomegaly, and/or collaterals). (the ultimate confirmation of the diagnosis of cirrhosis will be a baseline hvpg \> 5 mmhg) * planned anti-hcv therapy in the next 3 months exclusion criteria: * any clinically-evident complication of cirrhosis that defines decompensation : jaundice, ascites, variceal hemorrhage, overt hepatic encephalopathy) * hepatocellular carcinoma * co-infection with hbv or hiv * ongoing alcohol abuse * occlusive portal thrombosis, * presence of comorbid conditions conferring a life expectancy\<1 year, history of allergy to iodides, pregnancy

Keywords: icg arfi portal hypertension cirrhosis diagnostic study
application of high resolution diffusion-weighted mr imaging pulse sequence in head and neck, and prostate cancers

Conditions: Head and Neck Cancer; Prostate Cancer

Summary: magnetic resonance imaging (mri) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt. the purpose of this study is to determine if a new mr imaging method can help tumor evaluation in head and neck cancer or prostate cancer. the extra images will be obtained using diffusion-weighted magnetic resonance imaging which provides image contrast through detection of small restrictions in the movement of water molecules. this study may help us provide additional information about the tumor along with the picture of the organ.


Eligibility criteria:
inclusion criteria: * adults aged 18 and over. * men and women without regard to ethnic background. * patients/subjects able to give informed consent * patients/subjects whose weight does not exceed 275 lbs. * patient with a known or suspected head and neck cancer or prostate cancer scheduled for an mri scan as part of their routine care --or-- * volunteer with no history of the disease in that category. exclusion criteria: * patients who are unwilling or unable to undergo mri including patients with contra-indications to mri such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips.

Keywords: mri mr imaging pulse sequence high resolution diffusion-weighted questionnaire 12-033
sinonasal gas exchange dynamics

Conditions: Sinusitis

Summary: sinonasal gas exchange is facilitated by the unique anatomy and topography of the sinonasal interface that represents a collection of airfoils creating an aerodynamic structure. the airflow during respiration generates positive and negative pressures that power the gas exchange between the sinuses and the nose. major surgical alteration of the interface reduces the rate and velocity of the exchange. minimally invasive procedures aimed at preserving the natural anatomy, topography and aerodynamic configuration of the interface will have negligible effects on sinonasal gas exchange.


Eligibility criteria:
inclusion criteria: * control: * normal healthy adult volunteers ages 18-65, * without allergies by history and allergy test, * non-smoker, * not using steroids. study group 1: adult subjects who had maxillary sinus balloon sinuplasty (with intact uncinate and ethmoid complex) study group 2: adult subjects who had endoscopic maxillary antrostomy and uncinectomy. exclusion criteria: * active acute or chronic infection, * nasal polyps, * severe nasal or septal deformity, * cystic fibrosis, * systemic illness (diabetes, hypertension etc.), * vulnerable population (children, pregnant women, institutionalized individuals etc.) * severe nasal and/or septal deviation, * hypersensitivity or intolerance to study medications (topical and local anesthetics) any turbinate surgery.

Keywords: nitric oxide sinuplasty
initial manifestations of congestive heart failure in patients with nsteacs

Conditions: Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome

Summary: acute heart failure (hf) is a common complication of acute coronary syndrome (acs) associated with poor prognosis. diagnosis of congestive hf in patients with initial, non-severe symptoms and signs may be challenging and early stages of this complication may be missed. to assess severity of hf in patients with acs killip classification is widely used but it does not take into account mild manifestations of hf. thus, patients without rales in the lungs and/or s3 will be labelled as killip class 1. the aim of this study is to determine the frequency, risk factors, abilities for early diagnosis using routine medical evaluation and clinical significance of subclinical and mildly symptomatic congestive hf in patients with acs without persistent st-segment elevation (nsteacs). the study will include 200 patients with nsteacs without history of severe hf and overt signs of congestion at presentation. presence and severity of dyspnea (according to likert ans visual analog scales), physical signs of heart failure (respiratory rate, distention of jugular veins, s3), peripheral oxygen saturation by pulse oximetry, heart rate and signs of ischemia on ecg, signs of congestion according to lung and vena cava inferior ultrasound and chest x-ray/ct as well as levels of nt-probnp, hstn, crp and fabp at presentation will be evaluated. presence and severity of dyspnea, physical signs of heart failure, oxygen saturation, heart rate and signs of ischemia on ecg, lung and vena cava inferior ultrasound will be re-assessed after 6, 12 and 24 hours. during hospitalization occurrence or worsening of clinical hf. clinical events will be followed up to 12 months after hospitalization.


Eligibility criteria:
inclusion criteria: * patients hospitalized to the cardiac intensive care unit with acs without persistent st-segment elevation * signed informed consent exclusion criteria: * acs with persistent st-segment elevation * high probability of absence of acs * congestive rales in the base of lungs, cardiac asthma, pulmonary edema, cardiogenic shock, obvious edema, anasarca * history of severe chronic heart failure (iii-iv nyha class, obvious edema, anasarca) * continuous use of loop diuretics

Keywords: acute heart failure, congestive heart failure, non-st-segment elevation acute coronary syndrome, lung ultrasound, vena cava inferior ultrasound
evaluation of a motion-activated refusal-skills training video game for prevention of substance use disorder relapse

Conditions: Relapse; Opioid Use; Marijuana Usage

Summary: the project proposes to continue the development of an intervention for relapse prevention in the form of a professional quality video game which rewards drug-rejecting physical motions and spoken refusal phrases. phase i research findings showed that youth in recovery experienced increased low craving levels, strong levels of satisfaction, and interest in attending treatment sessions where the intervention is available - an important outcome since failure to attend treatment is highly correlated with relapse. in phase ii, the investigators propose to modify and expand the prototype based on customer feedback from treatment centers, counselors and patients. the investigators will test the effectiveness of the motion and voice-controlled game in a randomized controlled trial of youths in treatment for opioid use disorder who have access to the game for a month. the investigators will measure the effect of gameplay on successful completion of detoxification/inpatient treatment and rates of linkage to next level of outpatient treatment. the investigators will also measure the effect of gameplay compared to treatment as usual (tau) during a subsequent episode of outpatient treatment (following inpatient), on rates of treatment attendance, treatment retention, urine drug test results, substance use self-report, treatment alliance, drug craving, and treatment satisfaction.


Eligibility criteria:
inclusion criteria: * attending the mmtc inpatient program for primarily opioid or marijuana use disorder treatment * ability to speak english exclusion criteria: * presence of a comorbid psychiatric condition that would make participation unsafe (eg, acute suicidality or unstable psychosis) * pregnancy (because of the physical exertion required to play the game)
sp intravenous chemotherapy versus sp by hipec in stage ⅲ patients after d2 gastrectomy

Conditions: Stage Ⅲ Gastric Cancer

Summary: the study is designed to assess the safety and efficacy of s-1 plus cisplatin hyperthermic intraperitoneal chemotherapy in stage ⅲ patients after d2 gastrectomy

the study is a randomized clinical trial，and subjects wuill be assigned two arms: sp intravenous chemotherapy or sp by hipec .after 8 cycles treatment,we assess the safety and efficacy.

Eligibility criteria:
inclusion criteria: * 18 ≤ age ≤ 70 years old * histologically diagnosed as stageⅲ gastric adenocarcinoma，and perform d2 radical gastrectomy，as well as have not received any anti-tumor therapy：chemotherapy,biological treatment or molecular targeted therapy , etc. * the eastern cooperative oncology group (ecog) status ≤ 2 * having given written informed consent prior to any procedure related to the study * expected survival time ≥3 months exclusion criteria: * history of severe hypersensitivity reactions to the ingredients of s-1 or cisplatin * hemoglobin\<90g/l * inadequate hematopoietic function which is defined as below: * white blood cell (wbc) less than 3,500/mm\^3 * absolute neutrophil count (anc) less than 1,500/mm\^3 * platelets less than 80,000/mm\^3 * inadequate hepatic or renal function which is defined as below: * serum bilirubin greater than 2 times the upper limit of normal range * alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2.5 times the uln if no demonstrable liver metastases or greater than 5 times the uln in the presence of liver metastases * blood creatinine level greater than 1.5 times uln,creatinine clearance\<60ml/min * receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug * women who is pregnant or lactating or fertile women of child-bearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period (including male) * psychiatric disorder or symptom that makes participation of the patient difficult * myocardial infarction, existing serious or unstable angina, and patients with cardiac insufficiency in 6 months * severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure, poorly-controlled diabetes * known dpd deficiency * participate in other clinical trial before the start of this trial * patient compliance is bad or researchers believe that patients are not suitable for this treatment * known to have active hepatitis patients
measuring heart and lung function in critical care

Conditions: Respiratory Distress Syndrome, Adult; Critical Illness; Mechanical Ventilation Complication; Haemodynamic Instability; Gas Exchange Impairment

Summary: this is a feasibility study of the use of a novel technique called 'inspiwave' to measure heart and lung function in adult patients in critical care. the preliminary work has already been undertaken in animal models and in healthy volunteers. the ultimate aim of this study is to develop a clinical tool for measuring (and therefore being able to make treatment changes based on) indices of heart and lung function in critical care patients. this study is the first assessment of the technique in this population, and whilst we know it works in patients undergoing general anaesthesia, we now need to assess whether inspiwave can be used at all in critical care patients who may have much more physiological derangement. the purpose of this phase of the research is to determine whether it is feasible to use inspiwave in critical care. inspiwave generates a sinusoidally modulated tracer gas signal in the inspired air. it also measures the resulting signal in the expired air. the unique handling of this signal by the patient can used be to derive key variables related to cardiopulmonary function such as lung volume, pulmonary blood flow, the deadspace (wasted ventilation) and the degree to which ventilation and blood flow are non-uniform. these are 'vital signs' in sick patients, yet are currently technically difficult to measure, particularly non-invasively.


Eligibility criteria:
inclusion criteria: * patients requiring mechanical ventilation in a critical care area exclusion criteria: * decision of participant not to be included * consultee declaration not to be included * severely impaired gas exchange as declared by the managing clinician * oxygen requirement exceeding 90% fio2

Keywords: mechanical ventilation lung function cardiopulmonary monitoring
the role of topically dissolved oxygen (tdo) to ameliorate signs of photodamage

Conditions: Rosacea; Acne Vulgaris; Atopic Dermatitis; Seborrheic Dermatitis

Summary: this study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.


Eligibility criteria:
inclusion criteria: * subjects must be female, 25-60 years old in good general health; * subjects must be fitzpatrick types i, ii, iii, iv, v * subjects must be willing to forgo the use of facial cosmetics (e.g. facial moisturizers,creams, foundations, blush, etc.) during the course of the study. * subjects may only use facial regimen of products provided by sponsor(lipstick, lip gloss, and eye mascara permitted). exclusion criteria: * known sensitivity to any of the test material ingredients. * routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted) (one-8lmg or 325mg aspirin okay) (birth control is okay but needs to be reported). * use of topical otc/rx drugs or other cosmetics at the test sites. * immunological disorders such as hiv positive and systemic lupus erythematosus (interview only) * participation in any clinical study within the last four weeks. * pregnant or lactating women (interview only). * damaged skin in or around test sites (including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site).

Keywords: topically dissolved oxygen inflammatory cutaneous disease rosacea acne vulgaris atopic dermatitis seborrheic dermatitis photodamage
venoarterial pco2 difference /arteriovenous o2 content difference ratio as goal of early septic shock therapy

Conditions: Septic Shock

Summary: reducing tissue hypoxia is the ultimate goal of severe sepsis and septic shock therapy.venoarterial pco2 difference /arteriovenous o2 content difference ratio (△pco2/ca-vo2) is considered to be a good indicator of global anaerobic metabolism.the purpose of this study was to compare the efficacy of △pco2/ca-vo2 and central venous oxygen saturation (scvo2) in the treatment of severe sepsis and septic shock.


Eligibility criteria:
inclusion criteria: * severe sepsis and septic shock patients exclusion criteria: * \<18 years old * pregnant and breast-feed woman * ami * cerebral hemorrhage * contraindication for central venous catheter or arterial catheter; * brainstem death